Literature DB >> 14712292

Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children.

M Wilda1, J Bruch, L Harder, D Rawer, A Reiter, A Borkhardt, W Woessmann.   

Abstract

Burkitt's lymphomas (BLs) are characterized by an activated MYC gene that provides a constitutive proliferative signal. However, activated myc can initiate ARF-dependent activation of p53 and apoptosis as well. Data derived from cell culture and animal models suggest that the inactivation of the ARF-MDM-2-p53 apoptotic signaling pathway may be a necessary secondary event for the development of BL. This has not been tested in freshly excised BL tissue. We investigated the ARF-MDM-2-p53 pathway in tumor specimen from 24 children with sporadic BL/B-ALL. Direct sequencing revealed a point mutation in the p53 gene in four BL. Overexpression of MDM-2 was evident in 10 of the BL samples analyzed by real-time quantitative PCR. Deletion of the CDKN2A locus that encodes ARF or reduced expression of ARF could not be detected in any BL by fluorescence in situ hybridization analysis or real-time quantitative PCR, respectively. Our results indicate that the ARF-MDM-2-p53 apoptotic pathway is disrupted in about 55% of the cases of childhood sporadic BL. We suggest that in addition to the inactivation of the ARF-MDM-2-p53 protective checkpoint function other antiapoptotic mutations may occur in a substantial part of children with sporadic BL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712292     DOI: 10.1038/sj.leu.2403254

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.

Authors:  Ken H Young; Dennis D Weisenburger; Bhavana J Dave; Lynette Smith; Warren Sanger; Javeed Iqbal; Elias Campo; Jan Delabie; Randy D Gascoyne; German Ott; Lisa Rimsza; H Konrad Müller-Hermelink; Elaine S Jaffe; Andreas Rosenwald; Louis M Staudt; Wing C Chan; Timothy C Greiner
Journal:  Blood       Date:  2007-09-19       Impact factor: 22.113

2.  Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.

Authors:  Alexey V Danilov; Olga V Danilova; Jennifer R Brown; Arthur Rabinowitz; Andreas K Klein; Brigitte T Huber
Journal:  Exp Hematol       Date:  2010-09-24       Impact factor: 3.084

3.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.

Authors:  Julia Richter; Matthias Schlesner; Steve Hoffmann; Markus Kreuz; Ellen Leich; Birgit Burkhardt; Maciej Rosolowski; Ole Ammerpohl; Rabea Wagener; Stephan H Bernhart; Dido Lenze; Monika Szczepanowski; Maren Paulsen; Simone Lipinski; Robert B Russell; Sabine Adam-Klages; Gordana Apic; Alexander Claviez; Dirk Hasenclever; Volker Hovestadt; Nadine Hornig; Jan O Korbel; Dieter Kube; David Langenberger; Chris Lawerenz; Jasmin Lisfeld; Katharina Meyer; Simone Picelli; Jordan Pischimarov; Bernhard Radlwimmer; Tobias Rausch; Marius Rohde; Markus Schilhabel; René Scholtysik; Rainer Spang; Heiko Trautmann; Thorsten Zenz; Arndt Borkhardt; Hans G Drexler; Peter Möller; Roderick A F MacLeod; Christiane Pott; Stefan Schreiber; Lorenz Trümper; Markus Loeffler; Peter F Stadler; Peter Lichter; Roland Eils; Ralf Küppers; Michael Hummel; Wolfram Klapper; Philip Rosenstiel; Andreas Rosenwald; Benedikt Brors; Reiner Siebert
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

4.  Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis.

Authors:  Renren Wen; Yuhong Chen; Li Bai; Guoping Fu; James Schuman; Xuezhi Dai; Hu Zeng; Chunying Yang; Robert P Stephan; John L Cleveland; Demin Wang
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

5.  Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.

Authors:  Jie Ding; Gernot Polier; Rebecca Köhler; Marco Giaisi; Peter H Krammer; Min Li-Weber
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

6.  p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

Authors:  Duonan Yu; Martin Carroll; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

7.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

Review 8.  Mechanisms involved in Burkitt's tumor formation.

Authors:  M R Campanero
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

9.  Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.

Authors:  Jake Shortt; Benjamin P Martin; Andrea Newbold; Katherine M Hannan; Jennifer R Devlin; Adele J Baker; Rachael Ralli; Carleen Cullinane; Clemens A Schmitt; Maurice Reimann; Michael N Hall; Meaghan Wall; Ross D Hannan; Richard B Pearson; Grant A McArthur; Ricky W Johnstone
Journal:  Blood       Date:  2013-02-12       Impact factor: 22.113

10.  Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Authors:  H A Poirel; M S Cairo; N A Heerema; J Swansbury; A Aupérin; E Launay; W G Sanger; P Talley; S L Perkins; M Raphaël; K McCarthy; R Sposto; M Gerrard; A Bernheim; C Patte
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.